USA - NYSE:MED - US58470H1014 - Common Stock
ChartMill assigns a Buy % Consensus number of 47% to MED. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-02-19 | DA Davidson | Maintains | Neutral -> Neutral |
| 2024-11-05 | DA Davidson | Upgrade | Underperform -> Neutral |
| 2024-07-22 | DA Davidson | Maintains | Underperform -> Underperform |
| 2024-06-05 | DA Davidson | Downgrade | Neutral -> Underperform |
| 2024-04-30 | DA Davidson | Maintains | Neutral -> Neutral |
| 2024-02-21 | DA Davidson | Maintains | Neutral -> Neutral |
| 2023-10-13 | Stephens & Co. | Initiate | Equal-Weight |
| 2023-08-08 | DA Davidson | Maintains | Neutral -> Neutral |
| 2023-07-31 | DA Davidson | Maintains | Neutral -> Neutral |
| 2023-05-02 | DA Davidson | Maintains | Neutral |
| 2023-02-22 | DA Davidson | Maintains | Neutral |
| 2022-11-04 | DA Davidson | Downgrade | Buy -> Neutral |
| 2022-08-04 | DA Davidson | Maintains | Buy |
| 2022-08-04 | Jefferies | Downgrade | Buy -> Hold |
| 2022-06-02 | DA Davidson | Maintains | Buy |
| 2022-02-24 | DA Davidson | Maintains | Buy |
| 2021-11-08 | DA Davidson | Maintains | Buy |
| 2021-05-05 | DA Davidson | Maintains | Buy |
| 2021-02-26 | DA Davidson | Maintains | Buy |
9 analysts have analysed MED and the average price target is 15.3 USD. This implies a price increase of 28.25% is expected in the next year compared to the current price of 11.93.
The consensus rating for MEDIFAST INC (MED) is 46.6667 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
The number of analysts covering MEDIFAST INC (MED) is 9.